Christine Allen

Christine Allen is a Canadian professor and the first associate vice-president and vice-provost for strategic initiatives at the University of Toronto.[1] She served formerly as interim dean of the university's Leslie Dan Faculty of Pharmacy. She is co-founder of Nanovista, a company focused on imaging of tumors.[2] She also works as the associate editor of Molecular Pharmaceutics.[3]

This article is about the Canadian pharmaceutical scientist and academic administrator. For the Mexican astronomer, see Christine Allen (astronomer).
Christine Allen
Academic background
EducationUniversity of Ottawa (BS)
McGill University (PhD)
Academic work
DisciplinePharmacology
InstitutionsBC Cancer Agency
University of Toronto

Education and career

Allen earned a Bachelor of Science degree in biochemistry from the University of Ottawa and a PhD in chemistry from McGill University. She completed a post doc in the Department of Advanced Therapeutics at the BC Cancer Agency.[4]

Career

Prior to joining the University of Toronto in 2002 she worked as a scientist and assistant directors of materials research at Celator Pharmaceuticals.[3] Allen's research is focused on the field of drug delivery, in particular, micelles and gold nanoparticles for cancer therapy.[5][6] She has developed several block-co-polymers, particularly those with PEG, for delivery of cancer chemotherapeutics.[5] For cancer imaging as well as theranostic applications, the Allen lab has developed several gold nanoparticle carriers.[6]

Awards and recognition

Her platforms apply concepts in drug delivery, targeted drug delivery, as well as controlled release. She has numerous patents, over 90 publications,[3] and has received many awards including:

  • Fellow of the Canadian Academy of Health Sciences[7]
  • 2014 Gattefossé Canada/CSPS Award in Lipid-Based Drug Delivery[8]
  • 2011 CRS/Elsevier Journal of Controlled Release Jorge Heller Award for Outstanding Paper[9]
  • Innovation Award - Ontario Research and Commercialization Program, 2008
  • Career Award - Canadian Institutes of Health Research (CIHR)/Rx&D, 2004-2009
  • New Investigator Research Award - Association of Faculties of Pharmacy of Canada (AFPC)/AstraZeneca, 2006
  • Early Career Award - Canadian Society for Pharmaceuticals Sciences (CSPS)/GlaxoSmithKline, 2006

References
  1. Kalvapalle, Rahul (July 5, 2019). "Christine Allen appointed U of T's first associate vice-president and vice-provost, strategic initiatives". U of T News. Retrieved September 1, 2019.
  2. "Christine Allen Women enabling science to reach the people who need it". Johnson & Johnson Innovation Labs. Archived from the original on 1 November 2018. Retrieved 30 July 2018.
  3. "Christine Allen". Controlled Release Society. Retrieved 30 July 2018.
  4. Government of Canada, Natural Sciences and Engineering Research Council of Canada (2018-05-31). "NSERC - Christine Allen". Natural Sciences and Engineering Research Council of Canada (NSERC). Retrieved 2022-08-01.
  5. Houdaihed, L; Evans, JC; Allen, C (2017). "Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic". Mol. Pharm. 14 (8): 2503–2517. doi:10.1021/acs.molpharmaceut.7b00188. PMID 28481116.
  6. Her, S; Jaffray, DA; Allen, C (2017). "Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements". Adv Drug Deliv Rev. 109: 84–101. doi:10.1016/j.addr.2015.12.012. PMID 26712711.
  7. Kalvapalle, Rahul (September 20, 2019). "10 U of T researchers named fellows of the Canadian Academy of Health Sciences". U of T News. Retrieved October 4, 2019.
  8. Dou, Yannan; Zheng, Jinzi; Foltz, Warren; Weersink, Robert; Chaudary, Naz; Jaffray, David; Allen, Christine (25 September 2011). "Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice". Journal of Controlled Release. 178 (23): 69–78. doi:10.1016/j.jconrel.2014.01.009. PMID 24440663.
  9. Dunn, Michael; Zheng, Jinzi; Rosenblat, Joshua; Jaffray, David; Allen, Christine (25 September 2011). "APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes". Journal of Controlled Release. 154 (3): 298–305. doi:10.1016/j.jconrel.2011.05.022. PMID 21640146.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.